Aplidin

Phase 2Small molecule

PPharmaMar

Aplidin is one of 72 small molecule programs targeting Primary Myelofibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary MyelofibrosisActive, not recruiting

LymphomaActive, not recruiting

Prostate CancerActive, not recruiting

Primary MyelofibrosisPhase 2

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Aplidin

PPharmaMar

Phase 2

1 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma

Completed·PPharmaMar·Phase 2·NCT00884286·67 enrolled

Primary Myelofibrosis1 trial

Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

Completed·PPharmaMar·Phase 2·NCT01149681·12 enrolled

Prostate Cancer1 trial

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

Terminated·PPharmaMar·Phase 2·NCT00780975·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Aplidin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aplidin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aplidin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PharmaMar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPharmaMar

Aplidin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

Primary Myelofibrosis1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News